ACIU | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 20%

Performance

5 Days

-3.15%

1 Month

-16.06%

3 Months

-7.36%

6 Months

-14.24%

1 Year

-20.17%

2 Year

-20.17%

Key data

Stock price

$2.77

P/E Ratio

N/A

DAY RANGE

$2.66 - $2.86

EPS

N/A

52 WEEK RANGE

$2.44 - $4.00

52 WEEK CHANGE

-$20.17

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$301,784

AVERAGE 30 VOLUME

$258,146

Company detail

CEO: Andrea Pfeifer
Region: US
Website: acimmune.com
Employees: 140
IPO year: 2016

Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AC Immune SA discovers, designs, and develops medicines and diagnostic products. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease. It is also developing ACI-24, an anti-Abeta vaccine candidate, as well as completed Phase Ib clinical study for Down syndrome. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases.

ACIU - AC Immune SA